跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2019-003449-14-DE
EUCTR2019-003449-14-DE进行中（未招募）1 期

A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHERAPY IN PATIENTS WHO ARE ctDNA POSITIVE AFTER SURGICAL RESECTION OF STAGE II-III NON-SMALL CELL LUNG CANCER.

Genentech Inc.0 个研究点目标入组 80 人开始时间: 2020年5月19日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
80
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •- Age >= 18 years
  • •- Resected Stage II-III NSCLC per American Joint Committee on Cancer staging criteria, 8th revised edition
  • •- Complete R0 resection of Stage II or III NSCLC prior to enrollment and adequate recovery from surgery
  • •- Pathological evaluation of mediastinal lymph nodes preoperatively or intraoperatively
  • •- ctDNA (circulating tumor DNA) identified in plasma after resection of Stage II-III NSCLC and prior to start of adjuvant platinum-doublet therapy, as determined by central testing
  • •- Treatment with at least two cycles of adjuvant platinum-doublet chemotherapy regimens for resected NSCLC
  • •- No unequivocal evidence of disease after surgery and adjuvant platinum-doublet chemotherapy, as assessed on imaging computed tomography or magnetic resonance scans) within 28 days prior to randomization
  • •- Availability of adequate tumor material
  • •- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • •- Adequate hematologic and end-organ function
  • •- Negative HIV test at screening
  • •- Negative hepatitis B test at screening
  • •- Negative hepatitis C test at screening.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 40
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 40

排除标准

  • •- Patients with a known mutation in exons 18-21 of EGFR or with a known ALK or ROS alteration
  • •- History of malignancy other than disease under study within 5 years prior to enrollment, with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
  • •- Induction and neoadjuvant systemic therapy prior to resection of NSCLC
  • •- Radiotherapy prior to or after resection of NSCLC
  • •- Prior systemic investigational therapy
  • •- Prior anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, or a cancer vaccine
  • •- Treatment with systemic immunostimulatory agents within 6 weeks or 5 drug elimination half-lives, prior to initiation of study treatment
  • •- Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment
  • •- Treatment with monoamine oxidase inhibitors (MAOIs) within 3 weeks prior to initiation of study treatment or requirement for ongoing treatment with MAOIs
  • •- Active or history of autoimmune disease or immune deficiency
  • •- Known primary immunodeficiencies, either cellular or combined T-cell and B-cell immunodeficiencies
  • •- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
  • •- Significant cardiovascular disease
  • •- Major surgical procedure, other than for diagnosis or for resection of disease under current study, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • •- Known active or latent tuberculosis infection
  • •- Recent acute infection
  • •- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment
  • •- Prior allogeneic stem cell or solid organ transplantation
  • •- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
  • •- Known clinically significant liver disease
  • •- Previous splenectomy
  • •- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • •- Known hypersensitivity to Chinese hamster ovary cell products or any component of the atezolizumab formulation
  • •- Known allergy or hypersensitivity to any component of RO7198457
  • •- Pregnant or lactating women.

研究者

相似试验

进行中（未招募）
1 期
A Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients with Non-Small Cell Lung Cancer After Platinum Failure
EUCTR2013-001142-34-GBF. Hoffmann-La Roche. Ltd.287
进行中（未招募）
1 期
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILUREON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILUREMedDRA version: 16.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864
EUCTR2013-001142-34-ITF. Hoffmann-La Roche. Ltd.287
进行中（未招募）
1 期
A Study of the Efficacy and Safety of RO7198457 in Combination with Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Patients Who are CtDNA Positive after Surgical Resection of Stage II-III Non-Small Cell Lung Cancer.on-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2019-003449-14-GBGenentech Inc.80
进行中（未招募）
1 期
Clinical trial to test the efficacy and the safety of MPDL3280A compared with Docetaxel in patients with non-small cell lung cancer.ON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILUREMedDRA version: 16.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864
EUCTR2013-001142-34-SEF. Hoffmann-La Roche. Ltd.287
进行中（未招募）
1 期
A Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma.Advanced melanomaMedDRA version: 20.0Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-001773-24-DEGenentech Inc.132